Connect with us
Information

Australia
North America
World

Investing News NetworkYour trusted source for investing success

North America
Australia
World
My INN

Private Placements

Reports & Guides
- Market Outlook Reports
- Investing Guides
Button

Precious Metals
Battery Metals
Base Metals
Energy
Critical Minerals

lexaria bioscience

POPULAR ARTICLES

Lexaria Announces Positive Final Results from Human Pilot Study #5

Lexaria Announces Positive Final Results from Human Pilot Study #5

Lexaria Awarded Six Additional Patents

Lexaria Awarded Six Additional Patents

Lexaria Awarded Six Additional Patents

Lexaria Awarded Six Additional Patents

LATEST ARTICLES

THE FOCUS DOCTRINE: 5 Assets Securing the 2026 Biological Choke Point

THE FOCUS DOCTRINE: 5 Assets Securing the 2026 Biological Choke Point

THE FOCUS DOCTRINE: 5 Assets Securing the 2026 Biological Choke Point

THE FOCUS DOCTRINE: 5 Assets Securing the 2026 Biological Choke Point

Lexaria Releases Annual Letter from the CEO

Lexaria Releases Annual Letter from the CEO

Lexaria Releases Additional Results from its Successful Phase 1b Study GLP-1-H24-4

Lexaria Releases Additional Results from its Successful Phase 1b Study GLP-1-H24-4

Primary Endpoint Successfully Achieved in Lexaria's Phase 1b Study GLP-1-H24-4

Primary Endpoint Successfully Achieved in Lexaria's Phase 1b Study GLP-1-H24-4

Primary Endpoint Successfully Achieved in Lexaria's Phase 1b Study GLP-1-H24-4

Primary Endpoint Successfully Achieved in Lexaria's Phase 1b Study GLP-1-H24-4

Lexaria Bioscience Corp. Announces Closing of $3.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Lexaria Bioscience Corp. Announces Closing of $3.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Lexaria Bioscience Corp. Announces $3.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Lexaria Bioscience Corp. Announces $3.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Material Transfer Agreement Between Pharmaceutical Company and Lexaria is Extended

Material Transfer Agreement Between Pharmaceutical Company and Lexaria is Extended

Material Transfer Agreement Between Pharmaceutical Company and Lexaria is Extended

Material Transfer Agreement Between Pharmaceutical Company and Lexaria is Extended

Lexaria Bioscience Corp. Announces Closing of $4.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Lexaria Bioscience Corp. Announces Closing of $4.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Lexaria Bioscience Corp. Announces $4.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Lexaria Bioscience Corp. Announces $4.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Latest News

Red Mountain Mining Continues to Advance the United States Critical Minerals Portfolio

Raptor Completes Further Drilling at Chester Project

Ni-Co Energy Inc. Files Preliminary Prospectus for Proposed Initial Public Offering

NorthStar Gaming Provides Update on Strategic Priorities for 2026

Red Metals Corp Invites Shareholders and Investment Community to Visit Them at Booth 2538 at PDAC 2026 in Toronto, March 1-4

Outlook Reports world

Precious Metals
- Gold
- Silver
Battery Metals
Energy
- Uranium
- Oil and Gas

Base Metals
Critical Metals
- Rare Earths
Industrial Metals
Agriculture

- Cleantech
- Emerging Tech

- Biotech
- Cannabis

- Psychedelics
- Pharmaceuticals

Featured Stocks

Homerun Resources

HMR:CC

Steadright Critical Minerals

Steadright Critical Minerals (SCM:CC)

SCM:CC

LaFleur Minerals

LaFleur Minerals (LFLR:CC)

LFLR:CC

Silverco Mining

Silverco Mining (SICO:CC)

SICO:CC

xU3O8 (uranium.io)

xU3O8 (uranium.io) (None)

Earthwise Minerals

Earthwise Minerals (WISE:CC)

WISE:CC

More featured stocks

Browse Companies

Precious Metals
Battery Metals
Energy

Base Metals
Critical Metals

MARKETS

COMMODITIES

CURRENCIES